Fig 2: THBS1 is a target of miR-19a-3p. (a) Differential mRNAs in TCGABLCA dataset were depicted in a volcano plot (Q1: downregulated mRNAs; Q2: uprequlated mRNAs). (b) Venn diagram for discovering the target mRNAs of miR-19a-3p. (c) THBS1 level shown in normal tissue and BLCA tissue with blue denoting normal tissue and red denoting BLCA tissue. (d) The expression of THBS1 in SV-Huc-1, T24, 5637, and RT4 cells was assayed through qRT-PCR and Western blot. (e) DLR assay verified the targeted relationship of miR-19a-3p and THBS1. (f) Impact of miR-19a-3p-mimic on the THBS1 level in T24 cells assayed through qRT-PCR and Western blot. *p < 0.05.

Fig 3: THBS1 is degraded by Staufen1 mRNA decay. (A) THBS1 promoter activity is not affected by Stau1-KD in H460 cells. (B,C) THBS1 transcript half-life is increased by Stau1 knock-down. (D) THBS1 transcript half-life is increased by UPF1 knock-down. (E) Stau1 expression is rescued in sh1 and sh2 H460 cell lines by a plasmid encoding a Stau1 mRNA resistant to sh1 and sh2 mRNA degradation (pStau155Res) when compared to empty vector (pcDNA3). (F) THBS1 mRNA levels are strongly reduced when Stau1 is re-expressed in sh1 and sh2 cells. (Asterisks: * p < 0.05; ** p < 0.01 and *** p < 0.001 in two-tailed Student’s t-test).

Fig 4: Expression of F9 and TSP-1 in brain tissue exosomes from patients with TLE. (A,B) Western blots demonstrated that the levels of exosomal TSP-1 protein and exosomal F9 protein were not significantly different in the temporal lobe tissues of TLE patients (n = 4) compared with that of control patients (n = 4). Mean ± SEM Student’s t-test was performed.

Fig 5: Attenuation of THBS1 expression rescues the tRF-17-79MP9PP-mediated inhibitory effects on breast cancer cells. (A) The expression of THBS1 between cancer and normal samples in TCGA database. (B) Expression of THBS1 in breast cancer based on individual cancer stages in TCGA database. (C) Prognostic effect of THBS1 for breast cancer was displayed in TCGA database. (D) Protein levels in MCF-7 and BT549 cells transfected with THBS1 siRNA or siRNA negative control. (E) Western-blot analysis was used to detect THBS1 expression in cells transfected with tRF-17-79MP9PP inhibitor, si-THBS1 or negative control. (F) Cell viability of MCF-7 and BT549 cells after transfected with tRF-17-79MP9PP inhibitor, si-THBS1 or negative control was detected by CCK-8 assay. Cell Migration assays (G) and invasion assays (H) were performed in treated cells. *p < 0.05; *** p < 0.001 statistically significant.